AUTHOR INDEX

Alhava, E., 92
Amaha, K., 66
Armaganidis, A., 101
Azavorian, R., 173

Bauer, H., 22
Bellomo, R., 7
Böhrer, H., 22
Bongrand, P., 193

Clark, C., 208
Clavier, N., 112
Cook, D.J., 147, 155
Craft, M., 142
Crouser, E.D., 83, 200

Daniil, Z., 161
Delogu, G., 188
Domenighetti, G., 177
Dorinsky, P.M., 83, 200

Famularo, G., 188
Fracica, P.J., 72
Friedman, G., 183

Goldman, M., 183
Gouin, F., 193
Gowski, D.T., 13
Griffith, L.E., 155
Grimbergen, C.A., 56
Gutierrez, G., 1, 49, 208

Hainley, S., 208
Hartikainen, J., 92
Heemskerk, A.E.J., 120
Heino, A., 92
Hennekes, M.W.T., 120
Hirata, Y., 66
Hoffman, L.A., 13
Huang, Y.-C.T., 72
Huisman, E., 120

Iglesias, J., 51
Ippoliti, F., 188
Itoh, M., 66

Jankowski, S., 183
Johanns, C.A., 28
Julian, M.W., 83, 200

Kahn, R.J., 183
Kandrotas, R.J., 173
Katsouyianni, K., 161
Kellum, J.A., 7
Kernerman, P., 155
Koski, E.M.J., 92
Kotanidou, A., 101
Koutsoukos, E., 161
Kramer, D.J., 7

Lechner, A.J., 28
Lenti, L., 188
Lo Bosco, L., 188
Lutz, J., 13

McKinley, B.A., 214
Maini, B., 51
Marandola, M., 188
Marchant, A., 183
Marik, P.E., 51, 142
Martin, C., 193
Martin, E., 22, 137
Matuschak, G.M., 28
Mavrommatis, A., 101
Merasto, M.E., 92
Miro, A.M., 13
Mitaka, C., 66
Moon, R.E., 72
Motsch, J., 22

Nagura, T., 66
Nimkoff, L., 132

Papazian, L., 193
Parmley, C.L., 214
Payen, D.M., 112
Perret, C., 177
Piantadosi, C.A., 72
Pinsky, M.R., 7, 13, 56

Quinn, C., 132

Raggueneau, J.-L., 112
Raszynski, A., 173
Ritz, R., 177
Rohr, D., 22
Roussos, C., 101, 161

Sagy, M., 132
Saux, P., 193
Schaller, M.-D., 177
Schmidt, H., 22, 137
Schurando, P., 112
Secchi, A., 137
Sigler, D.W., 13
Signore, L., 188
Silver, P., 132
Simonson, S.G., 72
Soler, M., 173
Spaan, J.A.E., 56
Sussmane, J.B., 173
Suter, P.M., 177

Takala, J., 92
Tangelder, G.J., 120
Tasota, F.J., 13
Taylor, D.E., 208
Thijs, L.G., 120
Tsunoda, Y., 66

Van den Berg, P.C.M., 56
Van den Bos, G.C., 120
Van Lambalgen, A.A., 120
Vassilakopoulos, T., 161
Vincent, J.-L., 3
Vincent, J.L., 183
Viviand, X., 193

Weisbrode, S.E., 83, 200
Wellmann, R., 137
Welty-Wolf, K.E., 72
Wilson, K., 147
Wolfsdorf, J., 173

Young, S.L., 72

Zakynthinos, S.G., 101, 161
Zakynthos, E., 161
Zullo, T., 13

SUBJECT INDEX

Abdominal aortic aneurysm repair, pHi changes after volume replacement, 51-55
N-Acetylcysteine, for adult respiratory distress syndrome, 177-181
Acute lung injury, plasma ANP and BNP levels in, 66-70
Adult respiratory distress syndrome (ARDS)
  N-acetylcysteine for, 177-181
Adult respiratory distress syndrome (ARDS) (*Continued*)
  pressure support ventilation, 161-172
Air tonometry, of gastric mucosal carbon dioxide tension, 208-213
Albuterol, for PICU postextubation, 173-176
Analgesia, for tissue hypoxia, 43
Anesthetics, effects in brain edema, 132-136

ANP (atrial natriuretic peptide), in acute lung injury, 66-70
ARDS. *See* Adult respiratory distress syndrome
Arterial blood gas monitor, ex vivo, clinical trial of, 214-220
Atrial natriuretic peptide (ANP), in acute lung injury, 66-70

Bacteremia, fluid resuscitation effects on renal function, 120-130
Blood pH, in tissue hypoxia, 40
BNP (brain natriuretic peptide), in acute lung injury, 66-70
Brain capacity, intestinal size and, 49
Brain edema, intravenous anesthetics in, 132-136
Brain natriuretic peptide (BNP), in acute lung injury, 66-70
Bronchospasm, tracheal gas insufflation for, 13-20

Carbon dioxide tension, gastric mucosal
  during gradual intestinal ischemia, 92-97
  saline *vs.* air tonometry of, 208-213
Cardiac arrest patients, life-support preferences of, 155-159
Cardiopulmonary effects, of prolonged mechanical ventilation, 72-81
Cardiopulmonary resuscitation (CPR)
  in-hospital, outcomes analysis of, 142-145
  patients, life-support preferences of, 155-159
Catecholamines, for tissue hypoxia, 43
Cerebral perfusion pressure (CPP), in brain edema, intravenous anesthetic effects on, 132-136
Coronary artery bypass grafting, postoperative weaning, intrathoracic fluid volume changes in, 22-26
Cost containment, PICU postextubation treatment regimens, 173-176
CPP (cerebral perfusion pressure), in brain edema, intravenous anesthetic effects on, 132-136
CPR (cardiopulmonary resuscitation), in-hospital, outcomes analysis of, 142-145
Critical illness survival, increased oxygen transport and, 44-46
Crystalloid therapy, after AAA repair, pHi changes and, 51-55

DO_2. *See* Oxygen delivery
Dobutamine, during normotensive endotoxemia, 137-141
Do not resuscitate orders, futility rationale for, 142-145

Economics
  intensive care unit and, 147-150
  PICU postextubation treatment regimens and, 173-176
Endotoxemia
  metabolic acid production/clearance sites, 7-11
  normotensive, dobutamine effects in, 137-141
  renal function in, fluid resuscitation effects on, 120-130
Endotoxin-induced ileal injury, VO_2-DO_2 alterations and, 83-90, 200-206
Extravascular lung water (EVLW), during weaning of CABG patients, 22-26

Fluid resuscitation
  effect on renal function in bacteremia and endotoxemia, 120-130
  for tissue hypoxia, 43

Gastric intramucosal pH (pHi)
  changes after postsurgical volume replacement, 51-55
  in regional hypoxia, 42
Gastric intramucosal pH (pHi) (*Continued*)
  in tissue hypoxia, 41
Gastric mucosal carbon dioxide tension, saline *vs.* air tonometry of, 208-213
Gastric tonometry, in tissue hypoxia, 41
Gram-negative bacteremia, TNFR-Fc treatment for, 28-37

Heart failure, PEEP effects on thoracopulmonary compliance and hemodynamics in, 101-110
Heat shock protein 70 (HSP_{70}), in sepsis, 188-191
Hemodynamics
  effects of PEEP on, 101-110
  during gradual intestinal ischemia, 92-97
Hetastarch, after AAA repair, pHi changes and, 51-55
High-risk patients, life-support preferences of, 155-159
Histamine-2 receptor blockade, effect on tonometric gastric mucosal PCO_2 measurements, 208-213
HSP_{70} (heat shock protein 70), in sepsis, 188-191
Hypoxia, definition of, 39

ICP (intracranial pressure), in brain edema, intravenous anesthetic effects on, 132-136
ICU. *See* Intensive care unit
Ileal injury, endotoxin-induced, VO_2-DO_2 alterations in, 83-90, 200-206
Infrared spectrometry, 42
Intensive care unit (ICU)
  economics and, 147-150
  pediatric, postextubation treatment regimens comparison, 173-176
Interleukin 6, in septic shock, 183-186
Interleukin 10, in septic shock, 183-186
INTERSEPT study, 1
Intestinal ischemia, gradual, systemic/regional effects of, 92-97
Intestinal size, brain capacity and, 49
Intestinal villus blood flow, in normotensive endotoxemia, dobutamine effects on, 137-141
Intracranial aneurysm surgery, jugular bulb venous oxygen saturation monitoring for, 112-118
Intracranial pressure (ICP), in brain edema, intravenous anesthetic effects on, 132-136
Intrathoracic blood volume index (ITBVI), during weaning of CABG patients, 22-26
Intravenous polyvalent immunoglobulins (IVIG), phagocyte membrane receptors and, 193-198
Ischemia/reperfusion injury, VO_2-DO_2 endotoxin-induced alterations and, 200-206
ITBVI (intrathoracic blood volume index), during weaning of CABG patients, 22-26
IVIG (intravenous polyvalent immunoglobulins), phagocyte membrane receptors and, 193-198

Jugular bulb venous oxygen saturation ($SvJO_2$), monitoring, during intracranial aneurysm surgery, 112-118

Kidney function, in bacteremia and endotoxemia, fluid resuscitation effects on, 120-130

Lactate, blood, in tissue hypoxia, 40

Left ventricular output, after cardiac surgery, positive pressure inspiration and, 56-63
Life support preferences, in hospitalized patients, 155-159
Luminescent oxygen probes, 42
Lung, effects of prolonged positive pressure ventilation on, 72-81
Lung injury score, *N*-acetylcysteine for ARDS and, 177-181

Magnetic resonance spectroscopy, of regional hypoxia, 43
Mandatory rate ventilation, in adult respiratory distress syndrome, 161-172
Mechanical ventilation
  PICU postextubation treatment regimens, 173-176
  prolonged, cardiopulmonary effects of, 72-81
  PSV, in adult respiratory distress syndrome, 161-172
  for tissue hypoxia, 43-44
  weaning after CABG, intrathoracic fluid volume changes and, 22-26
Metabolic acid, production/clearance sites in endotoxemia, 7-11
Metacholine-induced bronchospasm, tracheal gas insufflation for, 13-20
Multiple organ dysfunction syndrome (MODS), tissue hypoxia in, 41-42

Near infrared spectrometry, 42
Nosocomial pneumonia, IVIG therapy, phagocyte membrane receptors and, 193-198

Outcomes analysis, of in-hospital CPR, 142-145
Oxygen consumption (VO_2)
  endotoxin-induced alterations, 200-206
  relationship to oxygen delivery, 49-50, 83-90
  in tissue hypoxia, 40
Oxygen delivery (DO_2)
  critical illness survival and, 44-46
  endotoxin-induced alterations, 200-206
  optimizing, for tissue hypoxia correction, 43
  relationship to oxygen consumption, 49-50, 83-90
  in tissue hypoxia, 40
Oxygen demand, reduction, for tissue hypoxia correction, 43-44
Oxygen saturation, mixed venous (SVO_2), in tissue hypoxia, 40-41

PaO_2/FIO_2, *N*-acetylcysteine for ARDS and, 177-181
PBVI (pulmonary blood volume index), during weaning of CABG patients, 22-26
δPCO_2 (veno-arterial carbon dioxide pressure gradient), in tissue hypoxia, 41
Pediatric intensive care unit (PICU), postextubation treatment regimens comparison, 173-176
PEEP. *See* Positive end-expiratory pressure
Penicillin
  discovery of, 1
  experimental work, 1
  phase II trials, 1-2
  phase I trials, 1-2
pH, blood. *See* Blood pH
Phagocyte membrane receptors, in IVIG patients, 193-198
pHi. *See* Gastric intramucosal pH
PICU (pediatric intensive care unit), postextubation treatment regimens comparison, 173-176
Pneumonia IVIG therapy, phagocyte membrane receptors and, 193-198
Polarographic oxygen electrodes, 42
Position emission tomography, of regional hypoxia, 43
Positive end-expiratory pressure (PEEP)
  effect on ventricular output after cardiac surgery, 56-63
  effects on thoracopulmonary compliance and hemodynamics, 101-110
Positive pressure ventilation (PPV), cardiopulmonary and morphological responses to, 72-81
Pressure support ventilation (PSV), in adult respiratory distress syndrome, 161-172
Pulmonary blood volume index (PBVI), during weaning of CABG patients, 22-26

Regional blood flow, in tissue hypoxia, 42
Right ventricular output, after cardiac surgery, positive pressure inspiration and, 56-63

Safety, of PICU postextubation treatment regimens, 173-176
Saline tonometry, of gastric mucosal carbon dioxide tension, 208-213
Sedation, for tissue hypoxia, 43
Sepsis
  heat shock protein 70 expression in, 188-191
  tumor necrosis factor-α in, 188-191
Sepsis clinical trials, 1, 2
  endpoints, 4-5
  megatrials, 3-4
  patient population, 3
  selection criteria, 4
  sepsis syndrome concept and, 3
  SIRS and, 3
Septic shock, severity, interleukin-10 blood levels and, 183-186
SIRS. *See* Systemic inflammatory response syndrome
Superior mesenteric artery occlusion, systemic/regional effects of, 92-97
SVO_2 (mixed venous oxygen saturation), in tissue hypoxia, 40-41
Systemic inflammatory response syndrome (SIRS)
  in sepsis clinical trials, 3
  tissue hypoxia in, 41-42

Thoracopulmonary compliance, effects of PEEP on, 101-110
Tissue hypoxia
  correction, 43-44
  definition of, 39-40
  detection of, 40-41
  global measurements, regional oxygenation and, 42
  in organ dysfunction in critical illness, 41-42
Tonometry, air *vs.* saline method, 208-213
Tracheal gas insufflation, for bronchospasm improvement, 13-20
Tumor necrosis factor-α
  reduction, during gram-negative bacteremia, 28-37
  in sepsis, 188-191
  in septic shock, 183-186
Tumor necrosis factor receptor:Fc, for gram-negative bacteremia, 28-37

Vasoactive drugs, for tissue hypoxia, 43

Veno-arterial carbon dioxide pressure gradient (δPCO_2), in tissue hypoxia, 41
Ventilation-perfusion distribution, after prolonged positive pressure ventilation, 72-81
Ventricular fibrillation patients, life-support preferences of, 155-159
Ventricular output, after cardiac surgery, positive pressure inspiration and, 56-63
VO_2. *See* Oxygen consumption

Weaning, intrathoracic fluid volume changes after CABG, 22-26